Incyte Corporation

124.28 +0.11(0.09%) Date:

Incyte Corporation

CS Decreased TP on Incyte Corporation by $7 on Baricitinib's Surprise CRL

Credit Suisse also notes that ~$130M of the $160M in baricitinib-related milestones could be at risk ($100M for US approval, ~$10M for Japanese approval, ~$30M for start of an additional ph3 program)

Guggenheim Believes Incyte Corporation (INCY) and Eli Lilly and Co (LLY) Will be Trading Down Tomorrow

Guggenheim has updated its Incyte and Eli Lilly models to include the impact of the CRL by pushing back the U.S. launch one year to 2Q18

Eli Lilly and Co (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) Received CRL for Baricitinib in RA

Higher proportion of patients with no radiographic progression and superiority to Humira was seen at 4mg dose

Incyte Corporation (INCY): Updated IDO Playbook

The firm continues to view the IDO space as an important and fast moving area of oncology research

Incyte Corporation (INCY): Multiple JAK Inhibitors In Clinical Development

Broad inhibition of JAK kinase may cause on-target toxicological effects leading to unwanted side effects